Setmelanotide (obesity and the control of hunger associated with deficiency in POMC, PCSK1 or LEPR, adults and children ≥ 6 years of age)
- Active Substance: Setmelanotide
- Name: Imcivree®
- Therapeutic area: Obesity and the control of hunger
- Pharmaceutical company: Rhythm Pharmaceuticals Inc.
- Start: 01.06.2022
- Final decision by G-BA: 01.12.2022
- Hint for a non-quantifiable additional benefit